PisitPitukcheewanontMD
Pediatric Endocrinology • Los Angeles, CAAssistant Professor, Pediatrics, USC School of Medicine
Are you Dr. Pitukcheewanont?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 27 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
4650 W Sunset Blvd
Los Angeles, CA 90027Phone+1 323-669-4606Fax+1 323-664-0337
Summary
- Dr. Pisit Pitukcheewanont, MD is a pediatric endocrinologist in Los Angeles, California. He is currently licensed to practice medicine in California, North Carolina, and Utah. He is affiliated with Children's Hospital Los Angeles and is an Assistant Professor at USC School of Medicine.
Education & Training
University of TennesseeResidency, Pediatrics, 1997 - 1997- University of TennesseeFellowship, Pediatric Endocrinology, 1994 - 1996
Chiang Mai University Faculty of MedicineClass of 1987
Certifications & Licensure
UT State Medical License 1900 - Present
CA State Medical License 1998 - 2026
NC State Medical License 1997 - 2003
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- The Effects of Vitamin D on Glycemic Control and Proinflammatory Markers in Adolescents With T1DM Start of enrollment: 2012 Oct 01
Publications & Presentations
PubMed
- 92 citationsDiagnosis of hidden central hypothyroidism in survivors of childhood cancer.Susan R. Rose, Robert H. Lustig, Pisit Pitukcheewanont, Dean C. Broome, George A. Burghen
The Journal of Clinical Endocrinology and Metabolism. 1999-12-01 - 14 citationsMucolipidosis type II (I-cell disease) masquerading as rickets: two case reports and review of literature.Maria Huei-Chun Lin, Pisit Pitukcheewanont
Journal of Pediatric Endocrinology & Metabolism. 2012-02-01 - 188 citationsA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: W...Karl L. Insogna, Karine Briot, Erik A. Imel, Peter Kamenický, Mary D. Ruppe
Journal of Bone and Mineral Research. 2018-08-01
Press Mentions
- Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call TranscriptMay 11th, 2022
